Fidelity MSCI Health Care Index ETF

FHLC

Market cap $3.24B

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund launched on October 21, 2013.

Fidelity MSCI Health Care Index ETF (FHLC) provides broad sector exposure with significantly lower fees than VanEck Biotech ETF (BBH). BBH focuses on just 25 holdings in the biotech space while FHLC holds more than 300 positions across the entire healthcare industry.

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

iShares Global Healthcare ETF provides exposure to international markets, while Fidelity MSCI Health Care Index ETF focuses exclusively on U.S.-based companies. Fidelity MSCI Health Care Index ETF maintains a significantly lower expense ratio than iShares Global Healthcare ETF.

Fidelity MSCI Health Care Index ETF (FHLC) offers a lower expense ratio and higher dividend than the iShares U.S. Healthcare ETF (IYH). IYH maintains a more concentrated portfolio, with 101 holdings compared to FHLC's 338 positions.

The Fidelity MSCI Health Care Index ETF (NYSEARCA:FHLC) is down about 5% year to date while the S&P 500 is up 7%.

Launched on October 21, 2013, the Fidelity MSCI Health Care Index ETF (FHLC) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Recent White House and FDA actions fast-track psychedelic depression drug approvals, granting priority review vouchers and accelerating rescheduling for eligible therapies. Compass Pathways leads with a CNPV for COMP360 in treatment-resistant depression, positive Phase 3 data, and a sub-$1bn market cap suggesting potential upside.

With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in revenue ($24.1 billion actual versus $23.6 expected) and earnings per share ($2.70 actual versus $2.66 expected).